Preclinical Evaluation of cRGD-Functionalized Lipid–Polymer Hybrid Nanocarriers for Anti-VEGF Gene Therapy in Triple-Negative Breast Cancer
Drug Development Research, cilt.87, sa.7, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 87 Sayı: 7
- Basım Tarihi: 2026
- Doi Numarası: 10.1002/ddr.70402
- Dergi Adı: Drug Development Research
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Natural Science Collection (ProQuest), Biological Science Database (ProQuest), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
- Anahtar Kelimeler: antiangiogenic therapy, antitumor activity, lipid polymer hybrid nanoparticle, targeted gene therapy, triple negative breast cancer
- Akdeniz Üniversitesi Adresli: Evet
Özet
Triple-negative breast cancer (TNBC) remains one of the most aggressive breast cancer subtypes owing to its high metastatic potential and the absence of effective molecularly targeted therapies. Although cRGD-functionalized nanocarriers have been extensively investigated for TNBC treatment, most reported systems primarily deliver chemotherapeutic agents or short regulatory RNAs. In the present study, we developed and preclinically evaluated a cRGD-functionalized lipid–polymer hybrid gene delivery system (cRGD-LPH-GDS) specifically engineered for the delivery of therapeutic plasmid DNA (pDNA) targeting the VEGF/VEGFR2 signaling axis. The nanosystem was prepared by a self-assembly approach using DSPE-PEG-Maleimide and cyclic arginine–glycine–aspartic acid (cRGD), yielding nanoparticles with a mean hydrodynamic diameter of 19.40 ± 0.43 nm, a zeta potential of +22.8 ± 1.6 mV, and a polydispersity index of 0.25. The hybrid formulation demonstrated effective protection of pDNA against serum- and DNase I-mediated degradation while maintaining reversible cargo release under destabilizing conditions. In vitro studies demonstrated acceptable cytocompatibility, enhanced receptor-mediated cellular uptake, improved transfection efficiency, and significant suppression of VEGF-A expression in 4T1 cells. Competitive receptor-blocking experiments further confirmed the contribution of αvβ3 integrin-mediated targeting to the enhanced biological activity of the targeted formulation. In an orthotopic 4T1 BALB/c mouse model, intratumoral administration of cRGD-LPH-GDS:pDNA significantly inhibited tumor growth, reduced intratumoral VEGF-A expression, and prolonged survival without evident systemic toxicity. Collectively, these findings demonstrate that integration of a lipid–polymer hybrid structure with therapeutic plasmid DNA delivery and cRGD-mediated targeting provides an effective non-viral system for anti-angiogenic gene therapy. The developed nanosystem represents a promising foundation for the further preclinical development of targeted pDNA delivery strategies for TNBC.